Pharmacokinetics of Ganaplacide and Lumefantrine in Adults, Adolescents, and Children with Plasmodium falciparum Malaria Treated with Ganaplacide Plus Lumefantrine Solid Dispersion Formulation: Analysis of Data from a Multinational Phase 2 Study.

No differences between body weight groups in exposure, in terms of C max and AUC 0‐24h , were apparent for ganaplacide or lumefantrine, although (consistent with the differences observed between Part A and B), a decreasing trend for ganaplacide C 168 h was observed in lower body weight groups (Tables 4 and 5 ).

also in 47,180 other papers